DOI: 10.1148/radiol.2301021482
Cost-Effectiveness of Uterine Artery Embolization and Hysterectomy for Uterine Fibroids1
Molly T. Beinfeld, MPH,
Johanna L. Bosch, PhD,
Keith B. Isaacson, MD and
G. Scott Gazelle, MD, MPH, PhD
1 From the Institute for Technology Assessment, Massachusetts General Hosp, 101 Merrimac St, 10th Floor, Boston, MA 02114 (M.T.B., J.L.B., G.S.G.); Dept of Radiology (M.T.B., J.L.B., G.S.G.) and Vincent Gynecology Service (K.B.I.), Massachusetts General Hosp, Harvard Med School, Boston; Dept of Health Policy and Management, Harvard School of Public Health, Boston, Mass (G.S.G.); Dept of Epidemiology and Biostatistics, Erasmus Univ Med Center, Rotterdam, the Netherlands (J.L.B.); and Dept of Medicine, Newton-Wellesley Hosp, Newton, Mass (K.B.I.). Received Nov 14, 2002; revision requested Jan 20, 2003; final revision received Jun 2; accepted Jun 18. Portions of this work are sponsored by the U.S. Dept of the Army under DAMD 17-99-2-9001. Address correspondence to G.S.G.

View larger version (33K):
[in a new window]
|
Figure 1. Schematic representation of decision model.
|
|

View larger version (18K):
[in a new window]
|
Figure 2. Graph illustrates results of two-way sensitivity analysis, with the utilities of cured after UAE and cured after hysterectomy varied. Two areas can be identified: one with UAE as the dominant treatment strategy (white area) and one with hysterectomy as the preferred option, given that society is willing to pay $75,000 or less per QALY (gray area). The arrows indicate the base-case values for utilities.
|
|
Copyright © 2004 by the Radiological Society of North America.